Evidence map›Paper›PMID 32527872›Full record

ArticleBMJ open respiratory research2020

Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas.

Emoke Papp, Anita Steib, Elhusseiny Mm Abdelwahab, Judit Meggyes-Rapp, Laszlo Jakab, Gabor Smuk, Erzsebet Schlegl, Judit Moldvay, Veronika Sárosi, Judit E Pongracz

Open access · goldAbstract read
In one paragraph

Article in BMJ open respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Emoke PappInternal Medicine, Pulmonology, The Medical School and Clinical Centre, University of Pecs, Pecs, Baranya, Hungary.
Anita SteibResearch, Humeltis Ltd, Pecs, Baranya, Hungary.
Elhusseiny Mm AbdelwahabPharmaceutical Biotechnology, Faculty of Pharmacy, University of Pecs, Pecs, Baranya, Hungary.
Judit Meggyes-RappResearch, Humeltis Ltd, Pecs, Baranya, Hungary.
Laszlo JakabSurgery, The Medical School and Clinical Centre, University of Pecs, Pecs, Baranya, Hungary.
Gabor SmukPathology, The Medical School and Clinical Centre, University of Pecs, Pecs, Baranya, Hungary.
Erzsebet SchleglTumour Biology, National Korányi Institute of Pulmonology, Budapest, Hungary.
Judit MoldvayTumour Biology, National Korányi Institute of Pulmonology, Budapest, Hungary.
Veronika SárosiInternal Medicine, Pulmonology, The Medical School and Clinical Centre, University of Pecs, Pecs, Baranya, Hungary.
Judit E PongraczPharmaceutical Biotechnology, Faculty of Pharmacy, University of Pecs, Pecs, Baranya, Hungary pongracz.e.judit@pte.hu.ORCID http://orcid.org/0000-0002-0278-5556
University of Pecs · HUOrszágos Korányi Tbc és Pulmonológiai Intézet · HUSemmelweis University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Despite improved screening techniques, diagnosis of lung cancer is often late and its prognosis is poor. In the present study, in vitro chemosensitivity of solid tumours and pleural effusions of lung adenocarcinomas were analysed and compared with clinical drug response.Methods Tumour cells were isolated from resected solid tumours or pleural effusions, and cryopreserved. Three-dimensional (3D) tissue aggregate cultures were set up when the oncoteam reached therapy decision for individual patients. The aggregates were then treated with the selected drug or drug combination and in vitro chemosensitivity was tested individually measuring ATP levels. The clinical response to therapy was assessed by standard clinical evaluation over an 18 months period.Results Based on the data, the in vitro chemosensitivity test results correlate well with clinical treatment response.Conclusions Such tests if implemented into the clinical decision making process might allow the selection of an even more individualised chemotherapy protocol which could lead to better therapy response.

Indexed as

AdenocarcinomaAntineoplastic AgentsDrug Screening Assays, AntitumorFeasibility StudiesHumansLung NeoplasmsPleural Effusion, MalignantPrognosisTumor Cells, CulturedAntineoplastic Agentslung cancerlung cancer chemotherapynon-small cell lung cancer

Identifiers

PMID32527872
PMCPMC7292226
OpenAlexW3035552291

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.